MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,208,300K
Net Income
$192,800K
Net Profit Margin
15.96%
EPS
$2.78
Unit: Thousand (K) dollars
Revenue Breakdown
Revenue From Contract With Custo...
High Sodium AGOxybate Product Ro...
Other Royalty And Contract Reven...
Revenue Breakdown
US
Europe
Other Countries
Revenue Breakdown
Product And Services Product Sal...
Product And Services Royalties A...
Revenue Breakdown
Xywav
Revenue From Contract With Custo...
Zepzelca
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
1,208,300
1,068,900
1,197,926
1,126,107
Cost of product sales (excluding amortization of acquired developed technologies)
116,400
134,100
153,528
128,880
Selling, general and administrative
389,200
352,700
406,212
530,647
Research and development
207,500
196,000
213,909
198,203
Intangible asset amortization
170,000
172,300
169,742
168,368
Acquired in-process research and development
77,000
-
0
42,500
Gain on sale of priority review voucher
0
122,800
-
-
Total operating expenses
960,100
732,300
943,391
1,068,598
Income (gain) from operations
248,200
336,600
254,535
57,509
Interest expense, net
-37,100
-39,900
-45,406
-48,576
Foreign exchange gain (loss)
-100
2,500
-658
102
Income (gain) before income tax expense (benefit) and equity in gain of investees
211,000
299,200
208,471
9,035
Income tax expense (benefit)
18,100
6,100
4,963
-242,424
Equity in loss of investees
-100
0
-57
-47
Net income (gain)
192,800
293,100
203,451
251,412
Basic EPS
3.05
4.73
3.332
4.14
Diluted EPS
2.78
4.43
3.383
4.08
Basic Average Shares
63,200,000
61,900,000
61,055,000
60,696,000
Diluted Average Shares
69,400,000
66,100,000
60,145,000
61,606,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
4
Revenue From Contract
With Customer...
$1,156,100K
(17.30%↑ Y/Y)
Product And Services
Product Sales Net Of...
$1,156,100K
(17.30%↑ Y/Y)
High Sodium
AGOxybate Product Royalty...
$42,200K
(-22.05%↓ Y/Y)
Other Royalty And
Contract Revenues
$10,000K
Total revenues
$1,208,300K
(15.55%↑ Y/Y)
Income (gain) from
operations
$248,200K
(136.16%↑ Y/Y)
Total operating
expenses
$960,100K
(-44.57%↓ Y/Y)
Income (gain) before
income tax expense...
$211,000K
(128.69%↑ Y/Y)
Interest expense, net
-$37,100K
(21.67%↑ Y/Y)
Foreign exchange gain
(loss)
-$100K
(94.44%↑ Y/Y)
Selling, general and
administrative
$389,200K
(8.59%↑ Y/Y)
Research and development
$207,500K
(9.23%↑ Y/Y)
Intangible asset
amortization
$170,000K
(4.87%↑ Y/Y)
Cost of product sales
(excluding amortization of...
$116,400K
(0.11%↑ Y/Y)
Acquired in-process
research and development
$77,000K
(-91.50%↓ Y/Y)
Net income (gain)
$192,800K
(126.83%↑ Y/Y)
Income tax expense
(benefit)
$18,100K
(205.42%↑ Y/Y)
Equity in loss of
investees
-$100K
(-16.28%↓ Y/Y)
Buy us a coffee
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)